CHA Biotech Co., Ltd. said on the 26th that its U.S. subsidiary, Matica Biotechnologies, has signed a contract development and manufacturing organization (CDMO) agreement for an adenovirus-based therapy with a major medical research institution in North America. The client’s name, contract value and project details were not disclosed by mutual agreement.
Under the agreement, Matica Biotechnologies will provide end-to-end services covering all stages from early process development to current Good Manufacturing Practice (cGMP) production for the client’s adenovirus therapy.
Specifically, the company will support research cell line development, process development, analytical development, quality testing, establishment of a master virus bank (MVB) and working virus bank (WVB), and cGMP production of adenoviral vectors.
The deal was driven by Matica Biotechnologies’ proprietary viral vector technologies and its CDMO capabilities spanning the full spectrum from early-stage research to commercialization.
Matica Biotechnologies has in-house platforms for retrovirus, lentivirus and adeno-associated virus, enabling rapid production of high-quality vectors. It also operates advanced CDMO facilities equipped with technologies that allow for fast and flexible responses to client needs.
Paul Kim, CEO of Matica Biotechnologies, said, “Leveraging our specialized adenovirus technology, we will support our client in advancing its therapy into the clinical development stage.”